Literature DB >> 3905816

Cleavage of bovine skin type III collagen by proteolytic enzymes. Relative resistance of the fibrillar form.

H Birkedal-Hansen, R E Taylor, A S Bhown, J Katz, H Y Lin, B R Wells.   

Abstract

We have studied the susceptibility of fibrils formed from fetal bovine skin type III collagen to proteolytic enzymes known to cleave within the helical portion of the molecule (vertebrate and microbial collagenase, polymorphonuclear elastase, trypsin, thermolysin) and to two general proteases of broad specificity (plasmin, Pronase). Fibrils reconstituted from neutral salt solutions, at 35 degrees C, were highly resistant to nonspecific proteolysis by general proteases such as polymorphonuclear elastase, trypsin, and thermolysin but were rapidly dissolved by bacterial and vertebrate collagenases at rates of 12-45 mol X mol-1 X h-1. In solution, type III collagen was readily cleaved by each of the proteases (with the exception of plasmin), as well as by the true collagenases, although at different rates. Turnover numbers determined by viscometry at 35 degrees C were: human collagenase, approximately equal to 1500 h-1; microbial (clostridial) collagenase, approximately equal to 100 h-1; and general proteases, 23-52 h-1. In addition it was shown that pronase cleaves type III collagen in solution at 22 degrees C by attacking the same Arg-Gly bond in the alpha 1(III) chain as trypsin. However, like other proteases, Pronase was rather ineffective against fibrillar forms of type III collagen. It was also shown that transition of type III collagen as well as type I collagen to the fibrillar form resulted in a significant gain of triple helical thermostability as evidenced by a 6.8 degrees C increase in denaturation temperature (Tm = 40.2 degrees C in solution; Tm = 47.0 degrees C in fibrils).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905816

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  A simple cost-effective methodology for large-scale purification of recombinant non-animal collagens.

Authors:  Yong Y Peng; Violet Stoichevska; Soren Madsen; Linda Howell; Geoff J Dumsday; Jerome A Werkmeister; John A M Ramshaw
Journal:  Appl Microbiol Biotechnol       Date:  2014-01-09       Impact factor: 4.813

Review 2.  Matrix metalloproteinase collagenolysis in health and disease.

Authors:  Sabrina Amar; Lyndsay Smith; Gregg B Fields
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-04-26       Impact factor: 4.739

Review 3.  Interstitial collagen catabolism.

Authors:  Gregg B Fields
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

4.  Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes.

Authors:  M W Ollert; R Söhnchen; H C Korting; U Ollert; S Bräutigam; W Bräutigam
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

5.  The role of collagen charge clusters in the modulation of matrix metalloproteinase activity.

Authors:  Janelle L Lauer; Manishabrata Bhowmick; Dorota Tokmina-Roszyk; Yan Lin; Steven R Van Doren; Gregg B Fields
Journal:  J Biol Chem       Date:  2013-12-02       Impact factor: 5.157

6.  Elastin in a neonatal rat smooth muscle cell culture has greatly decreased susceptibility to proteolysis by human neutrophil elastase. An in vitro model of elastolytic injury.

Authors:  P J Stone; M P McMahon; S M Morris; J D Calore; C Franzblau
Journal:  In Vitro Cell Dev Biol       Date:  1987-10

7.  The collαgen III fibril has a "flexi-rod" structure of flexible sequences interspersed with rigid bioactive domains including two with hemostatic roles.

Authors:  J Des Parkin; James D San Antonio; Anton V Persikov; Hayat Dagher; Raymond Dalgleish; Shane T Jensen; Xavier Jeunemaitre; Judy Savige
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

Review 8.  Resolution of Deep Venous Thrombosis: Proposed Immune Paradigms.

Authors:  J Matthew Nicklas; Aviva E Gordon; Peter K Henke
Journal:  Int J Mol Sci       Date:  2020-03-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.